RemeGen to close IPO early, JW Therapeutics prices

By Jonathan Breen
30 Oct 2020

Chinese biopharmaceutical firm RemeGen will close the international orderbook for its Hong Kong IPO early as the deal is already many times covered, according to a source close to the listing.

RemeGen began bookbuilding on Tuesday with sponsors Huatai Financial, JP Morgan and Morgan Stanley, aiming to raise up to HK$3.99bn ($514.7m) from its listing of 76.5m primary shares.

By Thursday, the bookrunners had the deal multiple times subscribed, on the back of demand from long-only funds and anchor ...

Already a subscriber?

Continue reading this article

Try full access to GlobalCapital

Free trial